Pacira BioSciences's latest marketcap:
As of 11/04/2025, Pacira BioSciences's market capitalization has reached $1.01 B. According to our data, Pacira BioSciences is the 10170th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.01 B |
| Revenue (ttm) | 705.85 M |
| Net Income (ttm) | -127,460,000 |
| Shares Out | 44.93 M |
| EPS (ttm) | -2.81 |
| Forward PE | 7.45 |
| Ex-Dividend Date | n/a |
| Earnings Date | 11/06/2025 |
Pacira BioSciences's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 11/04/2025 | $1.01 B | 10.44% | 10170 |
| 12/31/2024 | $869.9 M | -44.48% | 9568 |
| 12/29/2023 | $1.57 B | -11.56% | 6553 |
| 12/30/2022 | $1.77 B | -33.9% | 5786 |
| 12/31/2021 | $2.68 B | 3.1% | 5122 |
| 12/31/2020 | $2.6 B | 37.52% | 4543 |
| 12/31/2019 | $1.89 B | 6.88% | 4734 |
| 12/31/2018 | $1.77 B | -4.5% | 4326 |
| 12/29/2017 | $1.85 B | 53.3% | 4807 |
| 12/30/2016 | $1.21 B | -57.2% | 5711 |
Company Profile
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. is a leading biopharmaceutical company specializing in non-opioid pain management and regenerative health solutions for healthcare practitioners across the United States.
Key Products
- EXPAREL – A bupivacaine liposome injectable suspension designed for postsurgical pain management.
- ZILRETTA – A triamcinolone acetonide extended-release injectable suspension used to manage osteoarthritis and knee pain.
- iovera system – A handheld cryoanalgesia device that delivers controlled cold therapy to targeted nerves, blocking pain signals.
Innovative Pipeline
The company is developing PCRX-201, a novel gene therapy vector platform aimed at treating prevalent conditions like osteoarthritis through localized genetic medicine administration.
Strategic Partnerships
Pacira has a development, commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension for veterinary use.
Company Background
Originally founded as Pacira Pharmaceuticals, Inc. in 2006, the company rebranded to Pacira BioSciences, Inc. in April 2019. It is headquartered in Tampa, Florida.
Frequently Asked Questions
-
What is Pacira BioSciences's (PCRX) current market cap?As of 11/04/2025, Pacira BioSciences (including the parent company, if applicable) has an estimated market capitalization of $1.01 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Pacira BioSciences (PCRX) rank globally by market cap?Pacira BioSciences global market capitalization ranking is approximately 10170 as of 11/04/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.